Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
Morningstar8 天
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...